Accuray INC 10-K annual reports

Accuray Incorporated has restated its fiscal year 2025 financial statements and prior interim periods due to errors in remaining performance obligations disclosure and identified material weaknesses in internal controls.

Accuray Incorporated has successfully refinanced its debt, significantly reducing its net loss and achieving positive cash flow from operations, despite ongoing macroeconomic challenges and tariff impacts.

Accuray Incorporated's 10-K filing for fiscal year 2024 details the company's business, financial results, and strategic initiatives in the radiation therapy market.